Gene therapy for advanced rod-cone dystrophy
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new gene therapy for people with advanced rod-cone dystrophy, a genetic condition that causes progressive vision loss. The treatment is given as an injection into the eye, and the study aims to see if it is safe and if it can help improve or preserve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed genetic diagnosis of rod-cone dystrophy (an inherited retinal disease).
- The disease must be advanced in both eyes.
- You must have some history of useful vision (not just light perception).
- You must not have had gene therapy, stem cell therapy, or cell-based treatments before.
- You must not have had eye surgery within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with advanced retinal degeneration (RCD) to learn how the disease progresses over time. It does not test a new treatment, but the information may help design future treatments.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.